Abstract
We report that a-63-year-old woman developed Pneumocystis jiroveci pneumonia (PCP) as a complication from treatment with infliximab for rheumatoid arthritis. Although there was neither symptoms of dyspnea nor typical observations on a chest X-ray examination, low levels of oxygen saturation and findings of high-resolution chest computed tomographic scanning suggested a possibility of interstitial pneumonia. A polymerase chain reaction-based detection of Pneumocystis jiroveci in induced sputum allowed an early diagnosis of PCP and subsequent effective treatment.
MeSH terms
-
Anti-Infective Agents / therapeutic use
-
Antibodies, Monoclonal / adverse effects*
-
Antirheumatic Agents / adverse effects*
-
Arthritis, Rheumatoid / drug therapy*
-
Blood Gas Monitoring, Transcutaneous
-
Female
-
Humans
-
Immunocompromised Host
-
Infliximab
-
Middle Aged
-
Pneumocystis carinii / isolation & purification*
-
Pneumonia, Pneumocystis / chemically induced*
-
Pneumonia, Pneumocystis / diagnosis
-
Tomography, X-Ray Computed
-
Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
-
Tumor Necrosis Factor-alpha / immunology
Substances
-
Anti-Infective Agents
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
Tumor Necrosis Factor-alpha
-
Trimethoprim, Sulfamethoxazole Drug Combination
-
Infliximab